A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis

Prior treatment

• Medication or Treatment and Timeframe prior to baseline visit Use of medicated moisturizers (prescribed or over-the-counter) that are likely to impact participant’s AtD - 1 week Herbal or traditional treatments likely to impact participants AtD - 1 week TCS or TCI or topical JAKi - 1 week Systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, azathioprine, methotrexate, or any immunosuppressive therapy - 4 weeks Any biologic treatment for AtD, including but not limited to, dupilumab, tralokinumab, lebrikizumab or nemolizumab - 13 weeks for Dupilumab 15 weeks for Tralokinumab 18 weeks for Lebrikizumab 12 weeks for Nemolizumab For other biologics: 5 half-lives (if known) or 16 weeks, whichever is longer. Specific dermatological treatments include phototherapy, treatment with phototherapy (narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]) - 4 weeks Regular use (more than 2 visits per week) of a tanning booth/parlor - 4 weeks Any investigational drug - 8 weeks or within 5 half-lives (if known), whichever is longer Treatment with a live or live attenuated vaccine - 30 days of the baseline visit or planned to receive such vaccines during the study Any other biologic treatment including but not limited to TNF inhibitors (e.g., etanercept, adalimumab), IL inhibitors (e.g., tocilizumab, anakinra) or T-cell inhibitors (e.g., abatacept) Please note that inclusion of any prior biologic other than those mentioned in Inclusion Criteria #5 should be discussed with the Medical Monitor prior to enrollment - 5 half-lives (if known) or 16 weeks, whichever is longer B Cell-Depleting biologics, including rituximab - 6 months
• Any other concomitant skin disorder (e.g., generalized erythroderma such as Netherton’s Syndrome, or psoriasis), pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of AtD lesions or compromise participant safety.
• Chronic or acute infection requiring treatment with oral or IV antibiotics, antivirals, anti-protozoal, or antifungals within 4 weeks before the Screening visit or anytime between the Screening and Baseline visits.
• Superficial skin infections within 1 week before the Screening visit or active infections (including localized infections), or history of recurrent infections (excluding recurrent fungal infections of the nail bed)
• Known, pre-existing or suspected parasitic infection within 6 months before the Screening visit.
• Symptomatic herpes zoster within 3 months prior to screening

Other illness

• History of anaphylaxis as defined by the Sampson Criteria (Sampson, 2006)
• Uncontrolled hypertension.
• Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma (defined by an ACQ-5 score ≥1.5 or a history of ≥ 2 asthma exacerbations within the last 12 months requiring systemic [oral and/or parenteral] corticosteroid treatment or hospitalization for > 24 hours).
• History of significant allergies to monoclonal antibodies
• Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA, dermatosis, toxic epidermal necrolysis or Stevens-Johnson syndrome, and exfoliative dermatitis).
• Other types of eczema such as allergic contact dermatitis

• Participant and/or their LAR must sign and date an informed consent.
• Adult participants 18 years to 75 years of age • Country specific requirement: Participants from South Korea are required to be aged at least 19 years or greater in the study. Participants from Thailand are required to be aged at least 20 years or greater in the study.
• BMI within the range 18 - 39.9 kg/m2 (inclusive).
• Disease Characteristics • AtD defined by the AAD Consensus Criteria [Eichenfield, 2014] (see Appendix 8). • Diagnosis of AtD ≥1 year • An IGA score ≥3 at both the Screening and Baseline visits • AtD involvement of ≥10% BSA at both the Screening and Baseline visits • EASI score ≥16 at both the Screening and Baseline visits • Baseline pruritus numerical rating scale average score for maximum intensity of at least 3, based on the average of daily pruritus numerical rating scale scores for maximum itch intensity reported during the 7 days prior to randomization.
• AtD Medications: Biologic experienced participants: may have had exposure to 1 biologic therapy for atopic dermatitis such as, dupilumab, tralokinumab or lebrikizumab. Such participants must meet at least 1 of the following conditions: - Participants who stopped treatment due to non-response, partial response, loss of efficacy. - Participants who stopped treatment due to intolerance or AEs. Participants who have had prior exposure to a biologic therapy could have received it in either a marketed setting, or a research setting with documentation of the participants treatment allocation confirming prior exposure to active biologic therapy and not placebo OR • Biologic naive participants: who in addition to an inadequate response to optimization of non-pharmacological measures such as moisturizers, must meet at least 1 of the following conditions: • Participant with a recent history (≤6 months prior to the Screening visit) of inadequate response to a stable regimen of prescription topical medication • Participants for whom prescription topical medications are not tolerated • Participants where there is a concern for potential side effects, such as skin thinning or increased risk of hypothalamic-pituitary-adrenal suppression. Note: Inadequate response to a stable regimen of prescription topical medication (such as medium to high potency TCS or TCI) is defined as failure to achieve and maintain remission or low disease activity state (equivalent to an IGA score =0 [clear] to 2 [mild]) despite treatment for the recommended duration as per label or for the maximum duration recommended for the participant’s treatment, whichever is shorter.
• Apply a stable dose of non-medicated topical moisturizer at least twice daily for ≥7 days prior to the baseline visit.
• Completed electronic diary entries for PP-NRS for a minimum of 4 of 7 days preceding randomization.